Effect of granulocyte colony-stimulating factor combination therapy on efficacy of posaconazole (SCH56592) in an inhalation model of murine pulmonary aspergillosis.
Using an inhalation model of pulmonary aspergillosis, we observed modest differences in the survival rates of mice treated with granulocyte colony-stimulating factor (G-CSF) and posaconazole (POS) and those treated with POS alone. This finding is in contrast to a previous report that suggested that G-CSF had a significant antagonistic effect on the antifungal activity of POS.
Patera
Andriani C
AC
Schering-Plough Research Institute, Kenilworth, New Jersey 07033, USA. andriani.patera@spcorp.com
Menzel
Frederick
F
Jackson
Craig
C
Brieland
Joan K
JK
Halpern
Judy
J
Hare
Roberta
R
Cacciapuoti
Anthony
A
Loebenberg
David
D
D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D001229:Aspergillosis, Allergic Bronchopulmonary / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality; D004359:Drug Therapy, Combination; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D008168:Lung / Q000382:microbiology; D008297:Male; D051379:Mice; D016019:Survival Analysis; D014230:Triazoles / Q000627:therapeutic use*
D000935:Antifungal Agents; D014230:Triazoles; D016179:Granulocyte Colony-Stimulating Factor; C101425:posaconazole